The ASTMH Annual Meeting draws tropical medicine and global health professionals representing academia, foundations, government, not for profit organizations, non-governmental organizations, the private sector, military and private practice.
Keynote Address
Date: Wednesday, 13 November 2024
Time: 17:30-19:30
Speaker: Monique Wasunna, Africa Ambassador, DNDi
Symposia
The path towards a treatment for dengue: Endemic country leadership, progress, and perspectives
Date: Friday, 15 November 2024
Time: 10:15-12:00
Moderator: Isabela Ribeiro, Viral Diseases Cluster Director, DNDi
Speakers:
- Mauro Teixeira, UFMG, Brazil
- Richa Chandra, Novartis, India
- André Siqueira, Head of Dengue Global Programme, DNDi
- Steven Lim, Raja Permaisuri Bainun Hospital, Malaysia
Advancing research to improve treatment of neglected tropical diseases in children
Date: Friday, 15 November 2024
Time: 13:45-15:30
Moderator: María-Jesús Pinazo, Head of Chagas Disease, DNDi
Speakers:
- Jaime Altcheh, Paediatrician and Parasitologist, Ricardo Gutierrez Children’s Hospital
- Saschveen Singh, Tropical Infectious Disease Advisor, Médecins Sans Frontières USA
- Borna Nyaoke, Head of Mycetoma Disease, DNDi
- Peter Steinmann, Head of the Diseases and Programmes Unit, Swiss TPH
- Olaf Valverde, Clinical Project Leader (HAT), DNDi
Advances in Chagas disease diagnostic assays and testing strategies
Date: Saturday, 16 November 2024
Time: 12:45-14:30
Moderator: Daniel Bourque, Boston Medical Centre
Speakers:
- María-Jesús Pinazo, Head of Chagas Disease, DNDi
- Jeffrey Whitman, UCSF
- Alejandro Schijman
Will HAT be the next NTD to achieve global elimination?
Date: Sunday, 17 November 2024
Time: 11:30-13:15
Moderators: Emily Crowley, University of Warwick and Rachel Bronzan, Gates Foundation
Speakers:
- Representative from WHO
- Erick Mwamba Miaka, Ministry of Health, Democratic Republic of the Congo
- Stéphane Hugonnet, NTD HAT-Filarial-Chagas Cluster Director, DNDi
- Representative from Liverpool School of Tropical Medicine
- Kat Rock, University of Warwick
Posters
Fexinidazole in patients with human African trypanosomiasis due to trypanosoma brucei rhodesiense, towards an arsenic-free, first-line therapy Valverde O*, Tizgo Nyirenda W, Eriatu A, Lemerani M, Wamboga C, Baudin E, Alves D, Matovu E |
Efficacy and safety of thermotherapy in combination with miltefosine in comparison to miltefosine monotherapy for the treatment of New World cutaneous leishmaniasis: A phase III, open-label, multicenter, randomized trial Arana B, Pascale JM, Llanos-Cuentas A, Hueb M, Machado P, Soto J, Cota G, Rode J, Blum B, Boni M |